HERNÁNDEZ MIRAMONTES, JORGE ANTONI,HERNÁNDEZ VILLANUEVA, JORGE ALBERT
申请号：
GT201700149
公开号：
GT201700149A
申请日:
2017.06.27
申请国别(地区):
GT
年份:
2018
代理人:
摘要：
Currently, the treatment of patients with advanced nephropathy (stage 5) includes alternative renal therapy (hemodialysis, peritoneal dialysis or kidney transplantation).The cost of poor quality of life is extremely high. Our invention is a mixture of carbonate: calcium, dioxide, polydiacid, polydiacid and calcium, and any possible combination. This product is mainly used to treat patients with renal failure, hypertension or in the condition of negative nitric acid balance. The purpose of this product is to reduce the purity of urea and ammonia water, and at the same time through the formation of nitrate, nicotinate and Malalate trading.It promotes the biosynthesis of unnecessary amino acids； by treating cell-forming alpha cetaceans with glutamic acid, it produces glutamic acid and related amino acids, such as glutamic acid. This treatment can prevent, maintain and even enhance renal function. Among other patients, it delays renal failure and the urgent need for alternative kidney treatment. In other countries, it has been used as a complementary treatment for alternative kidney therapy to improve patients'quality of life and laboratory parameters.ACTUALMENTE EL TRATAMIENTO PARA PACIENTES CON ENFERMEDAD RENAL TERMINAL (ESTADIO V) CONSISTE EN TERAPIA RENAL SUSTITUTIVA (HEMODIÁLISIS, DIÁLISIS PERITONEAL O TRANSPLANTE RENAL)； EXTRAORDINARIAMENTE COSTOSA QUE CONLLEVA UN POBRE CALIDAD DE VIDA. NUESTRO INVENTO ES UNA MEZCLA DE ÁCIDOS CARBOXÍLICOS: ÁCIDO CÍTRICO, ÁCIDO SUCCÍNICO, ÁCIDO FUMÁRICO Y ÁCIDO MÁLICO, Y CUALESQUIERA DE SUS COMBINACIONES POSIBLES. DICHO PRODUCTO SE UTILIZA PREFERENTEMENTE VÍA ORAL O TAMBIÉN VÍA INTRAVENOSA, EN EL TRATAMIENTO DE PACIENTES CON INSUFICIENCIA RENAL CRÓNICA, HIPERAMONEMIA O CONDICIONES HUMANAS QUE CURSEN CON BALANCE NITROGENADO NEGATIVO. ESTE PRODUCTO ES BENÉFICO PARA DISMINUIR LOS VALORES SÉRICOS DE UREA Y DE AMONIO SÉRICO, A LA VEZ QUE POR TRANSAMINACIÓN DEL OXALACETATO FORMADO VÍA SUCCINATO, FUMARATO Y MALATO, PROMUEVE LA BIOSÍNTESIS
